Gameto received $10M in funding from ARPA-H to develop menopause-targeting therapies using a cell engineering platform.
Gameto received $10M in funding from ARPA-H to develop menopause-targeting therapies using a cell engineering platform.
10/24/24, 3:23 PM
Location
Money raised
$10 million
Industry
biotechnology
health care
Gameto has been awarded $10 million from the US Government’s ARPA-H initiative to advance its Ameno program, targeting menopause with innovative therapies. The funding will support the company's therapeutic development program, currently in preclinical stages, aimed at addressing critical challenges in women's health.
Company Info
Location
madison avenue
new york, new york, united states
Additional Info
Gameto is a biotechnology company developing novel treatment solutions for women's health, starting with infertility. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys. Gameto's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body.